91桃色

Immunodeficiencies, which impair the body’s ability to defend against infections and diseases, are increasingly recognized as a global public health issue. While these disorders are often thought of as rare, the rising prevalence of both primary immunodeficiencies (PIDs) and secondary immunodeficiencies (SIDs) highlights their growing impact on global health. Primary immunodeficiencies, caused by genetic mutations, often present at birth, whereas secondary immunodeficiencies are acquired later in life, frequently due to malnutrition, infections such as HIV, or medical treatments like chemotherapy or organ transplants. With advances in diagnostic tools and a better understanding of immunodeficiencies, public health experts are now seeing the broader implications of these conditions on disease spread, infection control, and overall healthcare systems [1]. This article provides an overview of the global epidemiology of immunodeficiencies, emphasizing their rising prevalence, regional disparities, and the need for improved diagnostic and management strategies to address this growing concern.

Description

The prevalence of primary immunodeficiencies

Primary immunodeficiencies are genetic disorders that result in a weakened or absent immune response. To date, over 450 different PIDs have been identified, including conditions such as Severe Combined Immunodeficiency (SCID), X-linked agammaglobulinemia, and Common Variable Immunodeficiency (CVID). While PIDs are often considered rare, their global prevalence is higher than previously understood. Estimates suggest that approximately 1 in 1,200 people may be affected by some form of PID, though this figure is likely an underrepresentation due to underdiagnosis, particularly in low- and middle-income countries (LMICs).

In high-income countries (HICs) like the United States, Europe, and parts of Asia, advances in genetic testing and newborn screening programs have dramatically increased the detection of PIDs. For example, widespread newborn screening for SCID has enabled early diagnosis and intervention, improving survival rates and reducing complications [2]. However, in LMICs, where access to advanced healthcare is limited, PIDs often go undiagnosed or are misdiagnosed as other common infections. This lack of diagnostic capacity contributes to significant morbidity and mortality, particularly in children who are more vulnerable to recurrent infections.

The burden of secondary immunodeficiencies

Secondary immunodeficiencies are far more common than PIDs and are caused by factors that suppress or weaken the immune system, including malnutrition, chronic diseases, infections, and medical interventions. HIV/AIDS remains the most well-known cause of SID, affecting millions of people worldwide. Sub-Saharan Africa continues to bear the brunt of the HIV/AIDS epidemic, with millions of immunocompromised individuals at risk for opportunistic infections, co-infections such as tuberculosis, and increased mortality [3].

In addition to HIV, other factors are contributing to a growing global burden of SIDs. Malnutrition, particularly in LMICs, compromises immune function and increases susceptibility to infections. In regions affected by food insecurity and poverty, conditions like protein-energy malnutrition and micronutrient deficiencies (e.g., vitamin A, zinc) are common causes of immune suppression. Furthermore, the rising incidence of non-communicable diseases (NCDs), such as cancer and diabetes, in both HICs and LMICs, is driving an increase in secondary immunodeficiencies. Immunosuppressive treatments for cancer and autoimmune diseases, including chemotherapy, organ transplants, and biologic therapies, also contribute to the growing prevalence of SIDs globally.

Regional disparities in immunodeficiency diagnosis and care

The epidemiology of immunodeficiencies reveals stark regional disparities in both diagnosis and access to treatment. In wealthier nations, immunodeficiencies are increasingly diagnosed early, often through comprehensive newborn screening programs or sophisticated genetic testing. Once diagnosed, patients have access to advanced treatments, including immunoglobulin replacement therapy, gene therapy, and hematopoietic stem cell transplantation. These interventions significantly improve life expectancy and quality of life for individuals with immunodeficiencies.

In contrast, in many low-resource settings, immunodeficiencies remain vastly underdiagnosed due to a lack of awareness, inadequate healthcare infrastructure, and limited access to diagnostic tools. Patients often present with recurrent infections, which are treated symptomatically without addressing the underlying cause. This not only leads to poor health outcomes but also contributes to the spread of infectious diseases in communities. The lack of access to life-saving treatments, such as immunoglobulin replacement therapy or even basic antibiotics, exacerbates the burden of immunodeficiencies in these regions [4].

Public health implications and challenges

The global rise in immunodeficiencies has significant public health implications. Immunodeficient individuals are more susceptible to infections, and their weakened immune systems can promote the evolution and spread of drug-resistant pathogens. In the context of emerging infectious diseases, immunodeficient populations may serve as reservoirs for novel infections, complicating outbreak control measures. Furthermore, the growing burden of SIDs, driven by the global HIV/AIDS epidemic and the increasing use of immunosuppressive therapies, places additional strain on healthcare systems, particularly in regions with limited resources [5].

Addressing the global burden of immunodeficiencies requires a concerted effort to improve diagnostic capacity, increase access to life-saving treatments, and implement public health strategies tailored to the unique needs of immunocompromised populations [6]. Education and awareness campaigns are essential for healthcare professionals and communities, particularly in LMICs, where immunodeficiencies are under-recognized. Expanding global access to essential therapies, such as immunoglobulin replacement and antiretroviral treatment for HIV, is also critical to reducing morbidity and mortality [7].

Conclusion

Immunodeficiencies, once considered rare disorders, are now recognized as a growing public health concern with significant global implications. The rising prevalence of both primary and secondary immunodeficiencies, along with disparities in diagnosis and care, underscore the need for enhanced public health strategies. While high-income countries have made strides in diagnosing and treating these conditions, many low- and middle-income countries continue to face significant challenges in managing immunodeficiencies. Addressing these challenges will require international collaboration, investment in healthcare infrastructure, and a focus on equitable access to care. As the global burden of immunodeficiencies continues to grow, it is essential that public health systems adapt to meet the needs of this vulnerable population.

Acknowledgement

None

Conflict of Interest

None

References

1. Wheeler SM, Bryant AS (2017) . Obstet Gynecol Clin North Am 44: 1-11.

, ,

2. Airhihenbuwa CO, Tseng TS, Sutton VD, Price L (2021) . Prev Chronic Dis 8: 18:E33.

, ,

3. Ramaswami R, Bayer R, Galea S (2018) . Annu Rev Public Health 39: 153-168.

, ,

4. Forde AT, Crookes DM, Suglia SF, Demmer RT (2019) . Ann Epidemiol 1-18.

, ,

5. Drenkard C, Lim SS (2019) . Curr Opin Rheumatol 31: 689-696.

, ,

6. Frohlich KL Potvin L (2008) . Am J Public Health 98: 216-221.

, ,

7. Southwell BG, Machuca JO, Cherry ST, Burnside M, Barrett NJ (2023) . Annu Rev Public Health 44: 113-130.

, ,